Next Article in Journal
Neuroprotective Effects of Pre-Treament with l-Carnitine and Acetyl-l-Carnitine on Ischemic Injury In Vivo and In Vitro
Next Article in Special Issue
ANRIL: Molecular Mechanisms and Implications in Human Health
Previous Article in Journal
PCR and Magnetic Bead-Mediated Target Capture for the Isolation of Short Interspersed Nucleotide Elements in Fishes
Previous Article in Special Issue
MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(2), 2063-2077; doi:10.3390/ijms13022063

ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a

Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
Research Laboratory of Virology, Immunology & Bioinformatics, Northwest A & F University, Xianyang 712100, Shaanxi, China
These authors contributed equally to this work.
Authors to whom correspondence should be addressed.
Received: 4 November 2011 / Revised: 3 February 2012 / Accepted: 7 February 2012 / Published: 15 February 2012
(This article belongs to the Special Issue Non-Coding RNAs)
View Full-Text   |   Download PDF [364 KB, uploaded 19 June 2014]   |  


Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disorder of skeletal malformations and progressive extraskeletal ossification. There is still no effective treatment for FOP. All FOP individuals harbor conserved point mutations in ACVR1 gene that are thought to cause ACVR1 constitutive activation and activate BMP signal pathway. The constitutively active ACVR1 is also found to be able to cause endothelial-to-mesenchymal transition (EndMT) in endothelial cells, which may cause the formation of FOP lesions. MicroRNAs (miRNAs) play an essential role in regulating cell differentiation. Here, we verified that miR-148a directly targeted the 3' UTR of ACVR1 mRNA by reporter gene assays and mutational analysis at the miRNA binding sites, and inhibited ACVR1 both at the protein level and mRNA level. Further, we verified that miR-148a could inhibit the mRNA expression of the Inhibitor of DNA binding (Id) gene family thereby suppressing the BMP signaling pathway. This study suggests miR-148a is an important mediator of ACVR1, thus offering a new potential target for the development of therapeutic agents against FOP.
Keywords: ACVR1; miR-148a; FOP; BMP; EndMT ACVR1; miR-148a; FOP; BMP; EndMT
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Song, H.; Wang, Q.; Wen, J.; Liu, S.; Gao, X.; Cheng, J.; Zhang, D. ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a. Int. J. Mol. Sci. 2012, 13, 2063-2077.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top